Conference Coverage
Conference Coverage
FDA’s Project Optimus aims to transform early cancer research
Q & A with an expert on how the FDA’s Project Optimus targets toxicity and how it could spell the end of traditional dose-escalation trials....
Conference Coverage
In MI with anemia, results may favor liberal transfusion: MINT
This study is “not a home run,” for the primary outcome, however, many of the outcomes tended to be in favor of a liberal transfusion strategy.
Conference Coverage
Particulate pollution increases the risk for breast cancer
“There is now strong epidemiological and biological evidence for the link between PM2.5 particulate exposure and cancer ...”
Conference Coverage
T-cell cancers: CAR T therapy to the rescue?
Trials are small and incomplete, but CAR T-cell therapy has yielded promising early results in treating T-cell blood cancers.
Conference Coverage
Gut microbiome variations may be predictive of precancerous colonic lesions, CRC
“We really need to find new predictors of tumorigenesis. We already have some good predictors, mainly FIT, but these are not enough. These gut...
Latest News
AI flagged skin cancer with near-perfect accuracy, in UK study
The researchers tested the AI by integrating it into a clinical diagnosis process - anticipating a future in which AI helps doctors catch skin...
Conference Coverage
Neoadjuvant, adjuvant, or both? The debate in NSCLC rages on
The question of whether to give upfront immunochemotherapy in resectable non–small cell lung cancer, wait until after surgery, or give both...
Conference Coverage
Two multitarget stool tests show promise for CRC screening: Studies
"This is the first large study to include the 45- to 49-year-old population, for whom screening is now recommended."
Conference Coverage
Rare lymphomas: Desperately seeking new txs
Experts seek global collaboration to develop novel therapies for peripheral T-cell lymphomas, a rare form of non-Hodgkin lymphoma with many...
Conference Coverage
‘We finally made it’: Amivantamab comes of age in NSCLC
Data from three trials with amivantamab in advanced EGFR-mutant NSCLC have yielded “exciting” results with experts hailing the drug as standard of...
